BioSpace News Archive

ZyVersa Therapeutics, Inc. announces that Stephen C. Glover, Co-Founder, Chairman, Chief Executive Officer, and President, will participate in BIO Partnering @ JPM being held January 8-12, 2024 in San Francisco.

Provectus (OTCQB: PVCT) today announced that the United States Patent and Trademark Office (USPTO) has allowed patent application 17/488,430, titled “Halogenated Xanthenes as Vaccine Adjuvants.”

Elutia Inc. (Nasdaq: ELUT) today announced it has submitted a 510(k) premarket notification to the U.S. Food and Drug Administration (FDA) for its next-generation drug-eluting biomatrix product, CanGarooRM®.

Notable Labs, Ltd. and CicloMed, LLC announced initial safety and efficacy data of fosciclopirox and the performance of PPMP, Notable’s Predictive Precision Medicines Platform, from the Phase 2a trial in adult patients with relapsed/refractory acute myeloid leukemia, R/R AML.

Anagenex and Nimbus Therapeutics announced they have initiated a research collaboration.

Lineage Cell Therapeutics, Inc. announced today that the Company has submitted an Investigational New Drug amendment (INDa) to the U.S. Food and Drug Administration (FDA), for OPC1.

Laxxon Medical today announced that management is scheduled to participate in the 26th Annual Needham Growth Conference on January 17th and 18th, 2024 in New York City.

Panbela Therapeutics, Inc. (Nasdaq: PBLA) today announced that US WorldMeds®1 (USWM), a Kentucky-based specialty pharmaceutical company to whom it divested certain assets in its eflornithine pediatric neuroblastoma program, received FDA approval of its New Drug Application (NDA) for the use of eflornithine as a maintenance therapy for high-risk neuroblastoma patients who have achieved at least a partial response to certain prior therapies.

Oncotelic Therapeutics, Inc, unveils a state-of-the-art GMP Manufacturing Plant, a significant stride in biopharmaceutical innovation, through its joint venture Sapu Biosciences LLC.

Waters Corporation announced that its Board of Directors has been named 2024 “Public Company Board of the Year” by the National Association of Corporate Directors New England Chapter.